No Data
Beijing SL Pharmaceutical (002038.SZ) has obtained the registration certificate for the pharmaceutical of desloratadine tablets.
Beijing SL Pharmaceutical (002038.SZ) announced that the company recently received the State Food and Drug Administration (referred to as the "National Drug...
Beijing SL Pharmaceutical (002038.SZ): Key products that have entered the national centralized procurement include the pharmaceuticals Temozolomide, Lenalidomide, and Ornidazole.
Gelonghui, November 13, 丨 Shuanglu Pharmaceutical (002038.SZ) said on November 12, 2024, that the company's key products that have entered national collection include temozolomide, lenalidomide, and ornidazole. Drugs that have entered interprovincial alliances and local collection include recombinant human granulocyte stimulating factor injections, thymus pentapeptides, interleukin-2, interleukin-11, and cyclosporine. Currently, most of the company's main varieties may have been included in the collection. Large and newly approved products , the company will replace it with the price
Beijing SL Pharmaceutical (002038.SZ): It is expected that next year's significant stock price fluctuations will not have a negative impact on the company.
On November 13th, Ge Longhui reported that Beijing SL Pharmaceutical (002038.SZ) stated during a specific object survey on November 12, 2024, that the situation is expected to improve next year. In the future, the company will participate in the national centralized procurement of most new varieties listed in the past one or two years, and will not be negatively impacted by significant price reductions. It may become a new source of growth. The company's financial assets are currently at relatively low levels, and it is expected that next year's significant fluctuations in stock prices will not adversely affect the company.
Shuanglu Pharmaceutical: Report for the third quarter of 2024
Beijing SL Pharmaceutical (002038.SZ): has already established an mRNA platform
Gelonghui October 21st | Beijing SL Pharmaceutical (002038.SZ) stated on the investor interaction platform that the company has established an mRNA platform, currently laying out in the fields of infectious disease treatment vaccines and tumor vaccines, and the related product research is still in the pre-clinical stage.
beijing sl pharmaceutical (002038.SZ): Executive Liang Shujie completes the shareholding of 0.5 million shares
On October 16, the Bejing SL Pharmaceutical (002038.SZ) announced that the company recently received a notice from senior executive Ms. Liang Shujie, informing the completion of the shareholding reduction plan, with a total reduction of 0.5 million shares, accounting for 0.0487% of the company's total share capital.
